“The outgoing CEO of AlmataBio (the private company AVTX is acquiring) is Patrick Crutcher, who used to be a co-moderator of this message board.”
Very cool. Sounds like he is going to make out quite well. The company is due 7.5 M in cash now and 5M upon dosing the first patient into phase 2 which is a near certainty, along with stock valued at 15M. Another 15M (cash and or stock ) if it makes it to phase 3. Good for him.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.